European Union - English - EMA (European Medicines Agency)

mylan s.a.s. - lopinavir/ritonavir - hiv infections - antivirals for systemic use, - lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infected adults, adolescents and children above the age of 2 years.the choice of lopinavir/ritonavir to treat protease inhibitor experienced hiv-1 infected patients should be based on individual viral resistance testing and treatment history of patients.

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - rivaroxaban - film-coated tablet - 10 milligram(s) - rivaroxaban

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - rivaroxaban - film-coated tablet - 15 milligram(s) - rivaroxaban

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - rivaroxaban - film-coated tablet - 20 milligram(s) - rivaroxaban

Ireland - English - HPRA (Health Products Regulatory Authority)

teva gmbh - rivaroxaban - film-coated tablet - rivaroxaban

Ireland - English - HPRA (Health Products Regulatory Authority)

teva gmbh - rivaroxaban - film-coated tablet - rivaroxaban

Ireland - English - HPRA (Health Products Regulatory Authority)

teva gmbh - rivaroxaban - film-coated tablet - rivaroxaban

Malta - English - Medicines Authority

medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - rivaroxaban - film-coated tablet - rivaroxaban 2.5 mg - antithrombotic agents

Malta - English - Medicines Authority

medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - rivaroxaban - film-coated tablet - rivaroxaban 10 mg - antithrombotic agents

Malta - English - Medicines Authority

medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - rivaroxaban - film-coated tablet - rivaroxaban 15 mg - antithrombotic agents